Traws Pharma, Inc. Announces Special Shareholders Meeting Results
Traws Pharma, Inc. (TRAW)
Company Research
Source: GlobeNewswire
Three proposals, including a reverse stock split, were submitted and approved Traws Board subsequently approved a 1-for-25 reverse stock split Traws’ shares expected to begin trading on a split-adjusted basis on September 23, 2024 NEWTOWN, Pa., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW) (“Traws” or “the Company”), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases and cancer, today announced the results of the Company’s 2024 Special Meeting of Stockholders held on September 16, 2024. At Traws’ 2024 Special Meeting of Stockholders on September 16, 2024, all of the matters put forward before the Company’s shareholders for consideration and approval, as set out in the Company’s definitive proxy statement dated August 8, 2024, were approved by the requisite number of votes cast at the meeting: Authorization of the issuance of shares of the Company
Show less
Read more
Impact Snapshot
Event Time:
TRAW
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRAW alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRAW alerts
High impacting Traws Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
TRAW
News
- Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Traws Pharma Provides Business Update and Reports Q3 2024 Financial ResultsGlobeNewswire
- Expert Systems Celebrates Milestone in Clinical Development of Tivoxavir Marboxil, Potential One-Time Influenza TreatmentPR Newswire
- Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir MarboxilGlobeNewswire
- Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro InhibitorGlobeNewswire
TRAW
Earnings
- 11/14/24 - Miss
TRAW
Sec Filings
- 11/15/24 - Form S-8
- 11/14/24 - Form 10-Q
- 11/14/24 - Form 8-K
- TRAW's page on the SEC website